Skip to content

The dose-response study of dexmedetomidine added to 0.075% ropivacaine for epidural analgesia in labor

The dose-response study of dexmedetomidine added to 0.075% ropivacaine for epidural analgesia in labor

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034367
Enrollment
Unknown
Registered
2020-07-03
Start date
2020-07-03
Completion date
Unknown
Last updated
2020-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epidural labor analgesia

Interventions

Group 2:0.075% ropivacaine group +0.1µg/ml dexmedetomidine
Group 3:0.075% ropivacaine group +0.2µg/ml dexmedetomidine
Group 4:0.075% ropivacaine group +0.3µg/ml dexmedetomidine
Group 5: 0.075% ropivacaine group +0.4µg/ml dexmedetomidine
Group 6: 0.075% ropivacaine group +0.5µg/ml dexmedetomidine

Sponsors

Zhejiang Xiaoshan Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) Maternity aged 18 to 40 years; (2) ASA 1-2 grade; (3) Height >= 150 cm, weight = 37 weeks; (5) Head position; (6) Cervical dilation 3-7cm; (7) VAS >= 30mm (0=not painful, 100=most painful); (8) Sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Contraindications to spinal canal anesthesia; (2) Those allergic to anesthetics, sufentanil or dexmedetomidine; (3) bradycardia; (4) multiple pregnancy; (5) pre-eclampsia; (6) Fetal abnormalities; (7) Other circumstances: history of cesarean section, long-term use of sedatives or analgesics.

Design outcomes

Primary

MeasureTime frame
The effective rate of labor analgesia after 30 minutes of epidural loading.;

Secondary

MeasureTime frame
Maternal basic information;Maternal vital signs;Sensorimotor block assessment;Labor time;Neonatal outcome;PCEA parameters;

Countries

China

Contacts

Public ContactJing Yu

Zhejiang Xiaoshan Hospital

2191200803@zju.edu.cn+86 18967168531

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026